BioSpace News Archive

Achieve Life Sciences, Inc. today provided an update on the cytisinicline clinical development program and announced third quarter 2018 financial results.

Intersect ENT, Inc. today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference on November 28 at the Lotte New York Palace in New York City, and will present in a session at 10:30am ET.

Novocure announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating Fields in Greater China and address questions from the audience.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2018 and provided a business update.

Quarter Highlighted by FDA Approval of COPIKTRA™ (duvelisib) Capsules

Investor Conference Call to be held 9:00 a.m. Eastern Time

VIVA Physicians announced the final five of 19 highly anticipated late-breaking clinical trial results at VIVA 18 hosted at the Wynn Las Vegas.

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe osteoarthritis-of-the-knee (OAK).

The Mesothelioma Compensation Center says, “We are urging a person with mesothelioma whose primary exposure to asbestos occurred at a public utility, water/sewer district, or any type of power plant to call us anytime at 800-714-0303 to make certain they are dealing directly with the nation’s leading mesothelioma attorneys as opposed to a local car accident attorney

TITAN Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern time.